Heart failure treatment study for people with preserved pumping function
Treatments studied
Part of Heart & circulation clinical trials.
This study tests an investigational medication called elecoglipron to see if it can improve heart and blood vessel outcomes in people with heart failure with preserved or mildly reduced ejection fraction. If you join, you will receive either the study drug or a placebo, and your heart health will be monitored over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure and are in New York Heart Association class II, III, or IV.
- Your ejection fraction (a measure of heart pumping strength) is greater than 40%.
- You have evidence of structural heart disease, like an enlarged heart or thickened heart muscle.
- Your body mass index (BMI) is 25 or higher.
- You do not have type 1 diabetes or poorly controlled diabetes (HbA1c below 10%).
- You have not had certain heart procedures or surgeries in the last 90 days, and you do not have other specific heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies people who have heart failure symptoms but whose heart pumping strength is largely preserved. It aims to better understand this specific type of heart failure and how best to treat or evaluate it.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This study looks at whether fat around the heart affects a type of heart failure where the heart pumps well but is stiff (HFpEF). You may be able to join if you have this condition, are 18 or older, and can understand English.
This study tests whether weight loss treatments can improve muscle and blood vessel function in people with a specific type of heart failure (HFpEF) who also have obesity. It may help if you have heart failure with a normal ejection fraction and a high BMI.
This trial tests an investigational drug called CK-4021586 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug is safe and well-tolerated. You may qualify if you are 40 to 85, have heart failure symptoms, and have a heart that pumps well but shows signs of strain.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
Hear when a new Heart Failure With Preserved Ejection Fraction (HFpEF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.